BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30803552)

  • 1. Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide.
    Baba SM; Shah ZA; Pandith AA; Dil-Afroze ; Jan A; Mir KA; Aziz SA; Ahmad Z
    Cancer Genet; 2019 Feb; 231-232():14-21. PubMed ID: 30803552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
    Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
    Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detecting PML-RARalpha transcript in acute promyelocytic leukemia using real-time quantitative RT-PCR.
    Zhu HH; Liu YR; Qin YZ; Jiang B; Shan FX; Wu SL; Yang PD; Zhao J; Lu DP
    Chin Med J (Engl); 2007 Oct; 120(20):1803-8. PubMed ID: 18028775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcription therapy for acute promyelocytic leukaemia.
    Douer D
    Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
    Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
    Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and clinical significance of real-time quantitative RT-PCR assay of PML-RARalpha fusion transcript in patients with acute promyelocytic leukemia.
    Gu BW; Hu J; Xu L; Yan H; Jin WR; Zhu YM; Zhao WL; Niu C; Cao Q; Su XY; Gu J; Ying HY; Chen Y; Xiong SM; Shen ZX; Chen Z; Chen SJ
    Hematol J; 2001; 2(5):330-40. PubMed ID: 11920269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia.
    Imaizumi M; Suzuki H; Yoshinari M; Sato A; Saito T; Sugawara A; Tsuchiya S; Hatae Y; Fujimoto T; Kakizuka A; Konno T; Iinuma K
    Blood; 1998 Jul; 92(2):374-82. PubMed ID: 9657734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.
    Santamaría C; Chillón MC; Fernández C; Martín-Jiménez P; Balanzategui A; García Sanz R; San Miguel JF; González MG
    Haematologica; 2007 Mar; 92(3):315-22. PubMed ID: 17339180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy.
    Ding W; Li YP; Nobile LM; Grills G; Carrera I; Paietta E; Tallman MS; Wiernik PH; Gallagher RE
    Blood; 1998 Aug; 92(4):1172-83. PubMed ID: 9694705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
    Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
    Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
    Tang FF; Lu SY; Zhao XS; Qin YZ; Liu XH; Jia JS; Wang J; Gong LZ; Jiang Q; Zhao T; Shi HX; Chang YJ; Huang XJ; Jiang H
    Br J Haematol; 2021 Dec; 195(5):722-730. PubMed ID: 34405393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
    Xu LW; Su YZ; Tao HF
    Curr Med Sci; 2021 Jun; 41(3):491-497. PubMed ID: 34169421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
    Ohnishi K
    Int J Clin Oncol; 2007 Oct; 12(5):313-7. PubMed ID: 17929112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
    Jing Y
    Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
    Kelly LM; Kutok JL; Williams IR; Boulton CL; Amaral SM; Curley DP; Ley TJ; Gilliland DG
    Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8283-8. PubMed ID: 12060771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.
    Chillón MC; Santamaría C; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Marín L; Caballero MD; Vidriales MB; Ramos F; Bernal T; Díaz-Mediavilla J; García de Coca A; Peñarrubia MJ; Queizán JA; Giraldo P; San Miguel JF; González M
    Haematologica; 2010 May; 95(5):745-51. PubMed ID: 20133893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a point mutation PML
    Zhao S; Shi P; Zhong Q; Shao S; Huang Y; Sun Y; Wu C; Zhu HH
    Biochem Biophys Res Commun; 2019 Apr; 511(3):518-523. PubMed ID: 30824184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acute promyelocytic leukemia: state-of-the-art management].
    Asou N
    Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute promyelocytic leukemia with a STAT5b-RARα fusion transcript defined by array-CGH, FISH, and RT-PCR.
    Chen H; Pan J; Yao L; Wu L; Zhu J; Wang W; Liu C; Han Q; Du G; Cen J; Xue Y; Wu D; Sun M; Chen S
    Cancer Genet; 2012 Jun; 205(6):327-31. PubMed ID: 22749039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
    Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
    Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.